p53MVA

AXP000187.1 · Cancer vaccine

Platform
MVA
Targets
TP53
Sponsor
City of Hope

Names

NameTypeSource
p53MVApreferred name, codecurator, ncit
MVA-p53codencit

Virus

Role
Vaccine vector
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
MVA
Replication
non replicating
Modifications
wild-type TP53 cassette inserted into MVA
Transgenes
TP53
Source
evidence

Cross-references

NCI Thesaurus
C116868

Approvals

No regulatory approval recorded.

Clinical trials (4)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT03113487P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive not recruitingPhase 22019-05-012022-08-2629Recurrent Platinum-Resistant Fallopian Tube Carcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma; Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
NCT02432963Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior TherapyActive not recruitingPhase 12015-12-282017-12-0411Adult Solid Neoplasm; Bladder Carcinoma; Colon Carcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Head and Neck Squamous Cell Carcinoma; Hepatocellular Carcinoma; Melanoma; Non-Small Cell Lung Carcinoma; Pancreatic Carcinoma; Progesterone Receptor Negative; Rectal Carcinoma; Renal Cell Carcinoma; Soft Tissue Sarcoma; TP53 Gene Mutation; Triple-Negative Breast Carcinoma; Unresectable Solid Neoplasm
NCT02275039p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial CancerCompletedPhase 12015-02-062018-04-2312Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Carcinoma
NCT01191684Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic CancerCompletedPhase 12011-12-222013-08-1912Recurrent Colon Cancer; Recurrent Gastric Cancer; Recurrent Pancreatic Cancer; Recurrent Rectal Cancer; Stage III Colon Cancer; Stage III Gastric Cancer; Stage III Pancreatic Cancer; Stage III Rectal Cancer; Stage IV Colon Cancer; Stage IV Gastric Cancer; Stage IV Pancreatic Cancer; Stage IV Rectal Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 30094792Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019name in title: p53MVA
PMID 29301826p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research2018name in abstract: p53MVA
PMID 24987057p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.Clinical cancer research : an official journal of the American Association for Cancer Research2014cited by trial NCT01191684

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 38032111Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer.Cancer research communications2023name in title: p53MVA
PMID 28049162Correction: p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses.Clinical cancer research : an official journal of the American Association for Cancer Research2017name in title: p53MVA
PMID 29209571Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab.Oncoimmunology2017name in title: p53MVA
PMID 25941580Overcoming immunosuppression to enhance a p53MVA vaccine.Oncoimmunology2014name in title: p53MVA
PMID 20551836Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression.Journal of immunotherapy (Hagerstown, Md. : 1997)2010name in abstract: p53MVA

Notes

MVA encoding wild-type human p53 (TP53); phase 1 trials at City of Hope, including with gemcitabine in recurrent ovarian cancer (NCT02275039, taken from trial listings, registry record not opened) and in refractory gastrointestinal cancers. Route not recorded here.

How to cite

p53MVA (AXP000187.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000187.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.